Collectively, our data identified a key regulator of the ER+ luminal lineage whose disruption may contribute to the development of ER+ luminal breast cancer when under the background of either TP53 or RB1 loss.
Collectively, our dataidentified a key regulator of the ER+ luminal lineage whose disruption may contribute to thedevelopment of ER+ luminal breast cancer when under the background of either TP53 or RB1 loss.